Research Analysis Reports Cystic Fibrosis | Page 2

Phone: 1-415-349-0054 Toll Free: 1-888-202-9519 Email: sales @ radiantinsights. com Web: http:// www. radiantinsights. com /
Scope
‣ To what extent is the CF market landscape expected to change with the introduction of new CFTR modulators?
‣ What are the clinical characteristics of currently approved therapies for CF, in terms of specific safety and efficacy parameters?
‣ What are the key unmet needs in this indication, and which clinical safety and efficacy parameters are the most closely linked to them?
‣ How will current late-stage CFTR modulators affect the market for symptomatic therapies, and are they able to yield comparable clinical efficacy results to Kalydeco?
‣ How will the influx of tobramycin generics affect the competitive landscape?
Reasons To Buy
‣ Understand the current clinical landscape by considering the treatment options available for each patient segment.
‣ Visually compare the currently approved treatments available at each line of therapy, based on the most important efficacy and safety parameters tested in clinical trials.
‣ Assess the current late-stage pipeline, in terms of the likely positioning of each product and the implications for the clinical landscape at each line of therapy.
‣ Understand the relative strengths and weaknesses of the studies used to gather these data.
‣ Build up a nuanced understanding of the clinical benchmarks set by these products, and consider how the current late-stage pipeline will affect these benchmarks.
‣ Assess your own pipeline programs in light of these benchmarks in order to optimally position them and maximize uptake by clinicians.
Browse Other Reports of This Category at: http:// www. radiantinsights. com / catalog / pharmaceuticals-and-healthcare
Table of Contents:
1. Report Guidance 3 2. Marketed Products 4 3. Antimicrobeals 4 4. Mucolytic Agents 5 5. Pancreatic Enzymes 6 6. CFTR modulators 6 7. Pipeline Products 8 8. Changes to Antimicrobeals, 2016-2022 8 9. Changes to Mucolytic Agents, 2016-2022 8 10. Changes to Pancretic Enzymes, 2016-2022 8 11. Changes to CFTR Modulators, 2016-2022 9
https
:// www. facebook. com / RadiantInsights
https:// www. linkedin. com / company / radiant-insights https:// twitter. com / radiantinsights
https:// plus. google. com /+ Radiantinsights